Vonoprazan
- Generic Name
- Vonoprazan
- Brand Names
- Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16FN3O2S
- CAS Number
- 881681-00-1
- Unique Ingredient Identifier
- 1R5L3J156G
- Background
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H, K-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthe...
- Indication
Vonoprazan, in combination with amoxicillin and clarithromycin in a co-packaged product, is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. Another co-packaged product with only vonoprazan and amoxicillin is also indicated for the treatment of H. pylori infection in adults.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastric or Duodenal Ulcers Caused by Low-dose Aspirin, Helicobacter Pylori Infection, Reflux Esophagitis (RE), Develop NSAID-induced gastric ulcers
- Associated Therapies
- -
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2023-02-16
- Target Recruit Count
- 393
- Registration Number
- NCT05419674
- Locations
- đ¨đł
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05366738
- Locations
- đşđ¸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05343364
- Locations
- đşđ¸
Infinite Clinical Trials, Morrow, Georgia, United States
đşđ¸Boston Specialists, Boston, Massachusetts, United States
đşđ¸University of South Alabama (USA) Physicians Group, Mobile, Alabama, United States
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 776
- Registration Number
- NCT05195528
- Locations
- đşđ¸
Paragon Rx Clinical, Garden Grove, California, United States
đşđ¸East View Medical Research, LLC, Mobile, Alabama, United States
đşđ¸Medical Affiliated Research Center Inc, Huntsville, Alabama, United States
The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 672
- Registration Number
- NCT05189444
- Locations
- đ¨đł
Tongji Hospital, Tongji Medical College, HUST, Wuhan, Hubei, China
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 300
- Registration Number
- NCT05014334
- Locations
- đ¨đł
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Uayporn Kaosombatwattana
- Target Recruit Count
- 194
- Registration Number
- NCT05005910
- Locations
- đšđ
Faculty of internal medicine siriraj hospital, Mahidol university, Bangkok Noi, Bangkok, Thailand
Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2021-06-01
- Target Recruit Count
- 234
- Registration Number
- NCT04907747
- Locations
- đ¨đł
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 458
- Registration Number
- NCT04799158
- Locations
- đşđ¸
North Alabama Research Center LLC, Athens, Alabama, United States
đşđ¸OM Research LLC, Lancaster, California, United States
đşđ¸Medication Management LLC, Greensboro, North Carolina, United States
A Study of Vonoprazan in Adults With Helicobacter Pylori
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 44
- Registration Number
- NCT04753437
- Locations
- đ¨đł
West China Hospital, Sichuan University, Phase I Unit, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.